Published in Proc Natl Acad Sci U S A on August 15, 2011
Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet (2012) 15.21
DNA methylation: roles in mammalian development. Nat Rev Genet (2013) 6.65
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Dynamic heterogeneity and DNA methylation in embryonic stem cells. Mol Cell (2014) 1.80
Epigenetics of reprogramming to induced pluripotency. Cell (2013) 1.73
Disentangling the many layers of eukaryotic transcriptional regulation. Annu Rev Genet (2012) 1.68
Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. Genome Res (2014) 1.63
Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping. Cell (2016) 1.41
The developmental dismantling of pluripotency is reversed by ectopic Oct4 expression. Development (2012) 1.33
Transcription factor binding dynamics during human ES cell differentiation. Nature (2015) 1.30
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
The evidence for functional non-CpG methylation in mammalian cells. Epigenetics (2014) 1.02
The roles of the reprogramming factors Oct4, Sox2 and Klf4 in resetting the somatic cell epigenome during induced pluripotent stem cell generation. Genome Biol (2012) 1.00
Do all roads lead to Oct4? the emerging concepts of induced pluripotency. Trends Cell Biol (2013) 0.98
DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics (2013) 0.96
Chemical methods for decoding cytosine modifications in DNA. Chem Rev (2014) 0.95
Molecular features of cellular reprogramming and development. Nat Rev Mol Cell Biol (2016) 0.93
A pooling-based approach to mapping genetic variants associated with DNA methylation. Genome Res (2015) 0.92
Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene. Mol Cell Biol (2014) 0.87
SNF5 is an essential executor of epigenetic regulation during differentiation. PLoS Genet (2013) 0.87
Epigenetic obstacles encountered by transcription factors: reprogramming against all odds. Curr Opin Genet Dev (2012) 0.87
Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure. PLoS Genet (2013) 0.86
Epigenetic diversity of Kaposi's sarcoma-associated herpesvirus. Nucleic Acids Res (2013) 0.86
Pluripotency transcription factor Oct4 mediates stepwise nucleosome demethylation and depletion. Mol Cell Biol (2015) 0.85
Identifying and characterizing regulatory sequences in the human genome with chromatin accessibility assays. Genes (Basel) (2012) 0.83
Multiplex mapping of chromatin accessibility and DNA methylation within targeted single molecules identifies epigenetic heterogeneity in neural stem cells and glioblastoma. Genome Res (2013) 0.83
Mechanisms for enhancing cellular reprogramming. Curr Opin Genet Dev (2014) 0.82
Transcriptional reprogramming and chromatin remodeling accompanies Oct4 and Nanog silencing in mouse trophoblast lineage. Stem Cells Dev (2013) 0.81
Altered promoter nucleosome positioning is an early event in gene silencing. Epigenetics (2014) 0.79
Nanog, Oct4 and Tet1 interplay in establishing pluripotency. Sci Rep (2016) 0.79
A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica (2012) 0.79
Transcriptional regulation of the potential tumor suppressor ABI3 gene in thyroid carcinomas: interplay between methylation and NKX2-1 availability. Oncotarget (2016) 0.79
Dynamic Enhancer Methylation - A Previously Unrecognized Switch for Tissue-Type Plasminogen Activator Expression. PLoS One (2015) 0.78
The H19 imprinting control region mediates preimplantation imprinted methylation of nearby sequences in yeast artificial chromosome transgenic mice. Mol Cell Biol (2012) 0.77
Nucleosomes are enriched at the boundaries of hypomethylated regions (HMRs) in mouse dermal fibroblasts and keratinocytes. Epigenetics Chromatin (2014) 0.77
p53 binding to human genome: crowd control navigation in chromatin context. Front Genet (2014) 0.77
Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression. Hum Mutat (2015) 0.76
Epigenetic Regulation of Caveolin-1 Gene Expression in Lung Fibroblasts. Am J Respir Cell Mol Biol (2016) 0.75
The pioneer factor OCT4 requires the chromatin remodeller BRG1 to support gene regulatory element function in mouse embryonic stem cells. Elife (2017) 0.75
Discussing epigenetics in Southern California: a report from the International Symposium on Epigenetic Control and Cellular Plasticity, UCI, December 15-16, 2011. Epigenetics (2012) 0.75
Sequence-directed nucleosome-depletion is sufficient to activate transcription from a yeast core promoter in vivo. Biochem Biophys Res Commun (2016) 0.75
dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression. Nucleic Acids Res (2017) 0.75
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Dynamic regulation of nucleosome positioning in the human genome. Cell (2008) 15.60
Stability and flexibility of epigenetic gene regulation in mammalian development. Nature (2007) 14.57
Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell (2008) 14.17
Chromatin signatures of pluripotent cell lines. Nat Cell Biol (2006) 12.88
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature (2007) 11.14
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet (2009) 6.50
Nucleosome dynamics define transcriptional enhancers. Nat Genet (2010) 5.94
Chromatin remodelling during development. Nature (2010) 5.86
H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. Nat Genet (2009) 5.82
G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol (2006) 5.16
Nucleosomes inhibit the initiation of transcription but allow chain elongation with the displacement of histones. Cell (1987) 5.00
An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell (2010) 5.00
Epigenetic reprogramming and induced pluripotency. Development (2009) 4.90
Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol (2005) 4.54
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol (2005) 3.97
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature (2010) 3.84
The logic of chromatin architecture and remodelling at promoters. Nature (2009) 3.63
An expanded Oct4 interaction network: implications for stem cell biology, development, and disease. Cell Stem Cell (2010) 3.60
De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nat Struct Mol Biol (2008) 3.33
What controls nucleosome positions? Trends Genet (2009) 3.15
A packing mechanism for nucleosome organization reconstituted across a eukaryotic genome. Science (2011) 2.95
Methylation of the Hprt gene on the inactive X occurs after chromosome inactivation. Cell (1987) 2.95
Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J (2003) 2.43
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
The dynamics of chromatin remodeling at promoters. Mol Cell (2005) 2.33
Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol Biol Cell (2007) 2.31
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
DNA methylation and cellular reprogramming. Trends Cell Biol (2010) 1.77
Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. Stem Cells (2010) 1.74
Gene regulation by nucleosome positioning. Trends Genet (2010) 1.69
DNA methylation increases nucleosome compaction and rigidity. J Am Chem Soc (2010) 1.67
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet (2011) 1.56
Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol (2005) 1.45
Epigenetic control of embryonic stem cell fate. J Exp Med (2010) 1.40
KLF4 and PBX1 directly regulate NANOG expression in human embryonic stem cells. Stem Cells (2009) 1.39
Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest (1993) 1.35
Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. Cancer Res (2009) 1.12
A structural perspective on the where, how, why, and what of nucleosome positioning. J Biomol Struct Dyn (2010) 0.95
Transcriptional and epigenetic regulations of embryonic stem cells. Mutat Res (2008) 0.88
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A (2004) 4.39
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
Rethinking how DNA methylation patterns are maintained. Nat Rev Genet (2009) 4.03
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood (2002) 3.89
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol (2002) 3.61
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
The CpG island searcher: a new WWW resource. In Silico Biol (2003) 3.42
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
DNA methylation and breast carcinogenesis. Oncogene (2002) 3.03
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res (2002) 3.02
DNA methylation: the nuts and bolts of repression. J Cell Physiol (2007) 3.00
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
Epigenetics and microRNAs. Pediatr Res (2007) 2.52
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A (2006) 2.25
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell (2011) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) (2008) 2.04
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Epigenetic changes in cancer. APMIS (2007) 1.96
Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res (2012) 1.95
Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res (2005) 1.94
H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell (2010) 1.85
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther (2005) 1.85
DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet (2011) 1.83
A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem Biol (2007) 1.78
DNA methylation and cellular reprogramming. Trends Cell Biol (2010) 1.77
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun (2008) 1.74
Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol (2005) 1.74
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res (2004) 1.69
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res (2004) 1.68
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol (2004) 1.68
Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res (2007) 1.65
Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer (2009) 1.64
Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res (2003) 1.62
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol (2011) 1.58
Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet (2011) 1.56
Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet (2006) 1.48
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget (2013) 1.44
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42
Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol (2005) 1.41
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res (2007) 1.40
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res (2007) 1.40
Emergency Department utilisation: a natural experiment. N Z Med J (2009) 1.39
Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol (2011) 1.34